Table 3.
Participant session attendance within dosage augmentations
| Augmentation | N a | Total # possible sessionsb | Attended Mean (M) | (%) |
|---|---|---|---|---|
| Baseline + step-up 1 | 3 | 3–17 | 5.2 | 81.3 |
| PA session | 3–17 | 6.7 | 62.5 | |
| HE session | 3–4 | 3.7 | 100.0 | |
| Baseline + step-up 1 + step-up 2c | 6 | 3–18 | 8.2 | 92.8 |
| PA session 1 | 7–18 | 12 | 98.5 | |
| PA session 2 | 3–10 | 4.8 | 79.8 | |
| HE Session | 7–8 | 7.7 | 100.0 | |
| Baseline + step-up 1 + step-up 2 + step-up 3c | 3 | 3–15 | 7.1 | 67.5 |
| PA session 1 | 11–15 | 12.7 | 93.9 | |
| PA session 2 | 8–11 | 6.7 | 78.8 | |
| PA session 3 | 3–7 | 1.3 | 33.3 | |
| HE session | 12 | 7.7 | 63.9 |
a
N = 12 (n = 1 participant received only baseline education/counseling and no adapted step-ups over the study period)
b
Range of possible sessions based on when each participant received the dosage augmentation
c
Combination of in-person and remote exercise sessions;
N number; PA physical activity; HE healthy eating, SR self-regulation